Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06600568
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-11
Brief Title:
Novel Therapeutic Approach for Human T-cell Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Identification of Targetable Vulnerabilities in Redox Homeostasis Pathways As a Novel Therapeutic Approach for Human T-cell Malignancies
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This multicenter translational study with prospective and retrospective samples aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels
Interactions between drugs capable of activating the apoptotic process eg Venetoclax and drugs capable of altering ROS homeostasis eg inhibitors of the enzyme glucose-6-phosphate dehydrogenase will be examined
The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory and then will be assayed ex vivo in cells obtained from patients with resistantrefractory T-cell neoplasms
Interactions between drugs capable of activating the apoptotic process eg Venetoclax and drugs capable of altering ROS homeostasis eg inhibitors of the enzyme glucose-6-phosphate dehydrogenase will be examined
The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory and then will be assayed ex vivo in cells obtained from patients with resistantrefractory T-cell neoplasms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None